NAS:ENDP (Ireland) Also trade in: Canada Germany UK

Endo International PLC

$ 5.95 -0.17 (-2.78%)
Volume: 3,140,382 Avg Vol (1m): 3,633,866
Market Cap $: 1.35 Bil Enterprise Value $: 8.48 Bil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -11.5
Net Current Asset Value -35.73
Tangible Book -32.99
Projected FCF 7.15
Median P/S Value 22.1
Graham Number 0
Peter Lynch Value 2.21
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.12
Cash-To-Debt ranked lower than
89.41% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
ENDP: 0.12
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.03, Med: 0.47, Max: 10000
Current: 0.12
0.03
10000
Equity-to-Asset -0.05
Equity-to-Asset ranked lower than
96.19% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
ENDP: -0.05
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.05, Med: 0.43, Max: 0.77
Current: -0.05
-0.05
0.77
Debt-to-Equity -16.41
Debt-to-Equity ranked lower than
100.00% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
ENDP: -16.41
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -1166.18, Med: 1.31, Max: 17.07
Current: -16.41
-1166.18
17.07
Debt-to-EBITDA 10.39
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
ENDP: 10.39
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1820.95, Med: 1.26, Max: 25.83
Current: 10.39
-1820.95
25.83
Interest Coverage 0.98
Interest Coverage ranked lower than
97.53% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
ENDP: 0.98
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.89, Med: 2.64, Max: 11.13
Current: 0.98
0.89
11.13
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.83
DISTRESS
GREY
SAFE
Beneish M-Score -2.65
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 8.06%
WACC 7.25%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 18.06
Operating Margin ranked higher than
60.80% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
ENDP: 18.06
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 10.5, Med: 20.44, Max: 31.42
Current: 18.06
10.5
31.42
Net Margin % -18.35
Net Margin ranked lower than
79.55% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
ENDP: -18.35
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -83.46, Med: -31.28, Max: 18.23
Current: -18.35
-83.46
18.23
ROA % -5.21
ROA ranked lower than
70.95% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
ENDP: -5.21
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -19.91, Med: -9.7, Max: 12.11
Current: -5.21
-19.91
12.11
ROC (Joel Greenblatt) % 17.24
ROC (Joel Greenblatt) ranked lower than
84.56% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
ENDP: 17.24
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -515.52, Med: -25.55, Max: 482.33
Current: 17.24
-515.52
482.33
3-Year Total Revenue Growth Rate -3.40
3-Year Revenue Growth Rate ranked lower than
68.21% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
ENDP: -7.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -12, Med: 18.6, Max: 26.9
Current: -7.4
-12
26.9
3-Year EPS w/o NRI Growth Rate -41.30
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
ENDP: -41.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» ENDP's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ENDP

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare HKSE:02616 SZSE:000078 BOM:524494 NAS:HRTX TSE:4521 NAS:PCRX SHSE:603567 NAS:TCDA SHSE:600267 TSX:APHA SZSE:000650 SZSE:300725 TSX:HEXO SZSE:300194 SZSE:300630 NAS:SUPN NAS:IRWD SHSE:600216 SHSE:600329 XSWX:SFZN
Traded in other countries EO7.Germany 0Y5F.UK
Address Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4
After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The recent acquisitions of Auxilium and Par have increased the company's presence in urology and generics, respectively. Branded drugs represent approximately 30% of revenue with the remainder in generics.

Ratios

Current vs industry vs history
Forward PE Ratio 2.89
Forward P/E ranked higher than
96.40% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
ENDP: 2.89
Ranked among companies with meaningful Forward P/E only.
N/A
PS Ratio 0.44
PS Ratio ranked higher than
80.13% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
ENDP: 0.44
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.33, Med: 1.67, Max: 6.03
Current: 0.44
0.33
6.03
Price-to-Free-Cash-Flow 26.06
Price-to-Free-Cash-Flow ranked higher than
89.93% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
ENDP: 26.06
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 3.25, Med: 8.4, Max: 2020.95
Current: 26.06
3.25
2020.95
Price-to-Operating-Cash-Flow 10.38
Price-to-Operating-Cash-Flow ranked higher than
89.80% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
ENDP: 10.38
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 2.51, Med: 7.79, Max: 156.75
Current: 10.38
2.51
156.75
EV-to-EBIT 98.40
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
ENDP: 98.4
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -40.6, Med: 5.4, Max: 112.1
Current: 98.4
-40.6
112.1
EV-to-EBITDA 10.89
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
ENDP: 10.89
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -2030.9, Med: 6.2, Max: 48.9
Current: 10.89
-2030.9
48.9
EV-to-Revenue 2.85
EV-to-Revenue ranked lower than
53.21% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
ENDP: 2.85
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.2, Med: 2.8, Max: 8.8
Current: 2.85
1.2
8.8
Current Ratio 1.30
Current Ratio ranked lower than
84.68% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
ENDP: 1.3
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.84, Med: 1.76, Max: 3.55
Current: 1.3
0.84
3.55
Quick Ratio 1.11
Quick Ratio ranked lower than
78.01% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
ENDP: 1.11
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.61, Med: 1.46, Max: 3.34
Current: 1.11
0.61
3.34
Days Inventory 76.89
Days Inventory ranked higher than
69.14% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
ENDP: 76.89
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 76.89, Med: 92.97, Max: 148.08
Current: 76.89
76.89
148.08
Days Sales Outstanding 60.03
Days Sales Outstanding ranked higher than
72.99% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
ENDP: 60.03
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 54.45, Med: 98.15, Max: 171.52
Current: 60.03
54.45
171.52
Days Payable 21.99
Days Payable ranked lower than
91.82% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
ENDP: 21.99
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 13.98, Med: 93.7, Max: 174.35
Current: 21.99
13.98
174.35

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.30
3-Year Share Buyback Rate ranked lower than
70.05% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
ENDP: -0.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -26.1, Med: -4.75, Max: 4.7
Current: -0.3
-26.1
4.7

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.83
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
78.07% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
ENDP: 0.83
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.39, Med: 0.71, Max: 2.28
Current: 0.83
0.39
2.28
Price-to-Median-PS-Value 0.27
Price-to-Median-PS-Value ranked higher than
74.56% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
ENDP: 0.27
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.25, Med: 1.64, Max: 4.95
Current: 0.27
0.25
4.95
Price-to-Peter-Lynch-Fair-Value 2.69
Price-to-Peter-Lynch-Fair-Value ranked lower than
100.00% of 212 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
ENDP: 2.69
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0, Med: 0.83, Max: 54.35
Current: 2.69
0
54.35
Earnings Yield (Joel Greenblatt) % 1.00
Earnings Yield (Greenblatt) ranked lower than
88.24% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
ENDP: 1
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -45, Med: 3, Max: 25.9
Current: 1
-45
25.9
Forward Rate of Return (Yacktman) % 67.49
Forward Rate of Return ranked higher than
98.81% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
ENDP: 67.49
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 4.3, Med: 27.8, Max: 67.49
Current: 67.49
4.3
67.49

More Statistics

Revenue (TTM) (Mil) $ 2,966.96
EPS (TTM) $ -2.42
Beta 2.29
Volatility % 99.34
52-Week Range $ 5.82 - 18.5
Shares Outstanding (Mil) 226.18

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y